Abstract 93P
Background
The TOPAZ-1 phase III trial reported a survival benefit with the anti-programmed death cell ligand 1 (anti-PD-L1) durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). The present study investigated for the first time the survival impact resulted from the addition of durvalumab to cisplatin/gemcitabine in a real-world setting.
Methods
The analyzed population included patients with unresectable, locally advanced, or metastatic BTC treated with durvalumab in combination with cisplatin/gemcitabine or cisplatin/gemcitabine alone. The impact of the addition of durvalumab to chemotherapy in terms of both overall survival (OS) and progression free survival (PFS) was investigated with uni- and multivariate analysis.
Results
Overall, 358 patients were included in the analysis: 213 received cisplatin/gemcitabine alone, 145 received cisplatin/gemcitabine plus durvalumab. At the univariate analysis, the addition of durvalumab resulted to have a survival impact, since the median OS was 11.2 Vs 12.9 months (HR 1.8, 95% CI 1.3-2.5, p=0.0005) in patients who received cisplatin/gemcitabine alone compared to those who received cisplatin/gemcitabine plus durvalumab. Moreover, patients who received cisplatin/gemcitabine alone showed worse PFS compared to those who received cisplatin/gemcitabine plus durvalumab (mPFS 6.0 Vs 8.9 months, HR 1.8, 95% CI 1.4-2.3, p<0.0001). The multivariate analysis confirmed that the addition of durvalumab to cisplatin/gemcitabine is a independent prognostic factor for both OS and PFS. Finally, an exploratory analysis of the prognostic factors in the cohort of patients who received durvalumab was performed: NLR>3 and ECOG PS>0 resulted to be independent prognostic factors in terms of both OS and PFS in this cohort of patients. The interaction test highlighted NLR>3 and ECOG>1 as predictive factors of response to cisplatin/gemcitabine plus durvalumab.
Conclusions
Accordingly to the results of the TOPAZ-1, the addition of durvalumab to cisplatin/gemcitabine has been confirmed to confer a survival benefit in terms of both OS and PFS in a real-world setting of advanced BTC patients.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
190P - Immune-related roles of B7H3 in glioblastoma
Presenter: Arnaud Simonet
Session: Poster Display
191P - Senolytic treatment remodels glioblastoma microenvironment
Presenter: Alexa Saliou
Session: Poster Display
192P - Analysis of Tumor-Associated Macrophages and Tumor-infiltrating Lymphocytes within the Tumor Microenvironment of Primary Tumors and Matched Brain Metastases
Presenter: Markus Kleinberger
Session: Poster Display
193P - Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibit anti-cancer immunity via CCL2
Presenter: Ronja Wieboldt
Session: Poster Display
194P - Achieving Reproducible Maturation Staging of Tertiary Lymphoid Structures: from Imaging Mass Cytometry Data to Pathology Applications
Presenter: Marion Le Rochais
Session: Poster Display
195P - IMMUcan - Toward a better understanding of the tumor microenvironment to inform precision oncology approaches.
Presenter: Marie Morfouace
Session: Poster Display
196P - Local glycan engineering induces systemic antitumor immune reactions via antigen cross-presentation
Presenter: Natalia Rodrigues Mantuano
Session: Poster Display
197P - Computational pathology pipeline enables quantification of intratumor heterogeneity and tumor-infiltrating lymphocyte score
Presenter: Daniel Tiezzi
Session: Poster Display
198P - Polarization of tumor-associated macrophages enhanced by 2-HP-_-cyclodextrin modified PLGA nanoparticles
Presenter: HAO YUAN
Session: Poster Display
199P - Scalable multiplexed image analysis across cancer types as part of the IMMUcan consortium
Presenter: Nils Eling
Session: Poster Display